Borderline Personality Disorder

The Study Drug known as either selegiline 12 mg patch or matching placebo patch will be administered daily beginning at Visit 2 for the duration of 12 weeks.

Selegiline

Transdermal Placebo patch manufactured to mimic Transdermal Selegiline 12 mg. patch

Placebo (for Selegiline)

Mood and Anxiety Research, Inc

Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder

A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety

The study subject will complete the SCL 90-R questionnaire at each visit on arrival at the office prior to meeting with the research staff. This will serve as the primary efficacy measure of outcome for the study. This instrument has been utilized in clinical trials since the early 1960s, and has a good ability to measure overall levels of psychological and physical functioning in this patient group.

Clinician will administer the HAM-D scale to subject at each visit to assess any changes in their overall symptoms, functioning social and daily life.

Clinician will assess any improvement in their overall symptoms, functioning social and daily life beginning at week 3(Visit 3)through week 12 (Visit 6).

Patient will assess any improvement in their overall symptoms, functioning social and daily life beginning at week 3(Visit 3)through week 12 (Visit 6).

Patient will assess any improvement in their overall functioning in their work / school, social and daily life at 3 time points

Study subjects will be monitored for safety throughout the study beginning at the Screening Visit (V1). At each visit, subjects will have various clinical, laboratory and safety measurements conducted. Results will be assessed by the clinical team and will be monitored, at each visit, until the term of their participation. A 2 week, post-study, follow-up will be conducted by the study staff.

noradrenalin/höfuðverkur

Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum